Boston Pharmaceuticals
Boston - Model BOS-228 -Novel Monobactam
BOS-228 is a novel monobactam for infections caused by multidrug-resistant carbapenem-resistant Enterobacteriaceae.
Most popular related searches
immune inflammatory
in vivo study
in vivo studies
inflammatory immunity
inflammatory immune
infection resistant
- BOS-228 provides single-agent coverage of both metallo- and serine-β-lactamase producing Enterobacteriaceae unlike others in the same class.
- Clinical PK and in vivo PK/PD studies support attainment of efficacious clinical exposures.